mTORC2 inhibition may offer a promising therapeutic strategy to help eradicate HER2-amplified breast cancers, in particular in tumors which are resistant to HER2 targeted therapy or where AKT signaling is activated. This evidence concerns the gene ERBB2 and breast cancer.